- Available:In stock1293
- Availability date:2020-07-30
- Dosage form:Tablets
- In stock:1293 Items
as a bactericidal and fungistatic agent, dequalinium chloride affects microorganisms that cause mixed infections of the oral cavity and throat. the range of action of this local chemotherapeutic agent is wide and includes most gram-positive and gram-negative bacteria, as well as fungi, spirochetes and pathogenic microorganisms that cause mixed infections of the oral cavity and throat. the accumulation of dibucaine hydrochloride in the body alleviates the pain symptom accompanying infections of the oral cavity and throat.
Microorganisms resistant to dequalinium chloride are unknown.
Does not cause caries.
Pharmacokinetics The main active ingredient is absorbed in very small amounts.
Local treatment for acute inflammatory diseases of the oral cavity and throat: gingivitis, ulcerative and aphthous stomatitis, tonsillitis, laryngitis and pharyngitis. Amylar ic is also recommended in the presence of halitosis.
Amylar IC can be used in case of a mixed infection of the oral cavity and throat (as recommended by a doctor) as an adjuvant for catarrhal tonsillitis, lacunar tonsillitis and Plauta-Vincents tonsillitis; in case of candidiasis of the oral cavity and pharynx.
Recommended in the postoperative period after tonsillectomy and tooth extraction.
Adults and children over the age of 12 years: 1 tablet every 2 hours, after reducing the severity of the symptoms of inflammation - 1 tablet every 4 hours.
For children over the age of 4 years: 1 tablet every 3 hours, after reducing the severity of the symptoms of inflammation - 1 tablet every 4 hours.
The maximum daily dose is 10-12 tablets during the acute phase and 6 tablets after the disappearance of inflammatory symptoms.
Dissolve the tablets slowly, without chewing. The duration of the course of treatment is determined by the doctor individually. The patient should consult a doctor if, after 5 days of treatment, the symptoms have not disappeared or worsened.
Hypersensitivity to any of the substances that make up the drug. allergy to quaternary ammonium compounds (e.g. benzalkonium chloride).
Hypersensitivity reactions after using the drug are sometimes possible, for example, rash, itching, burning, irritation of the mucous membrane of the oral cavity and throat. in rare cases, namely abuse, the occurrence of ulcers and necrosis is possible. in case of any unusual reactions, discontinue use of the drug and be sure to consult a doctor regarding further therapy.
Since the drug does not contain sugar, it is suitable for use in patients with diabetes mellitus.
The drug contains sorbitol, so it should not be used in patients with rare hereditary diseases, such as fructose intolerance syndrome. Use with caution in patients with low plasma cholinesterase.
Use during pregnancy and lactation. Pregnancy. No controlled studies have been performed. With this in mind, the drug during pregnancy can be used after consulting a doctor if the therapeutic effect exceeds the possible risk to the fetus.
The period of breastfeeding. No clinical studies have been conducted on the penetration of active substances into breast milk. The drug is not recommended for use during lactation.
Children. The drug in this dosage form is not prescribed for children under the age of 4 years.
The ability to influence the reaction rate when driving vehicles or working with other mechanisms. Studies on the effect of the drug on the ability to drive vehicles or work with mechanisms have not been conducted.However, the likelihood that the drug may have some kind of negative effect in this regard is very low.
The antibacterial activity of dequalinium is reduced while it is used with anionic tensides, such as toothpaste. the use of the drug should not be combined with cholinesterase inhibitors.
There are no data on overdose.
In the original packaging at a temperature not exceeding 25 ° C.